POSEIDA THERAPEUTICS INC (PSTX) Stock Fundamental Analysis

USA • Nasdaq • NASDAQ:PSTX • US73730P1084

9.5 USD
-0.06 (-0.63%)
At close: Jan 7, 2025
9.54 USD
+0.04 (+0.42%)
After Hours: 1/7/2025, 8:07:14 PM
Fundamental Rating

2

PSTX gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 524 industry peers in the Biotechnology industry. Both the profitability and financial health of PSTX have multiple concerns. While showing a medium growth rate, PSTX is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • In the past year PSTX has reported negative net income.
  • In the past year PSTX has reported a negative cash flow from operations.
  • In the past 5 years PSTX always reported negative net income.
  • In the past 5 years PSTX always reported negative operating cash flow.
PSTX Yearly Net Income VS EBIT VS OCF VS FCFPSTX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 -50M -100M

1.2 Ratios

  • With a decent Return On Assets value of -20.70%, PSTX is doing good in the industry, outperforming 77.25% of the companies in the same industry.
  • PSTX has a Return On Equity of -69.67%. This is comparable to the rest of the industry: PSTX outperforms 56.08% of its industry peers.
Industry RankSector Rank
ROA -20.7%
ROE -69.67%
ROIC N/A
ROA(3y)-36.56%
ROA(5y)-40.69%
ROE(3y)-77.72%
ROE(5y)-80.34%
ROIC(3y)N/A
ROIC(5y)N/A
PSTX Yearly ROA, ROE, ROICPSTX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 0 200 -200 400 600 800 1K

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for PSTX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PSTX Yearly Profit, Operating, Gross MarginsPSTX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 -200 -400 -600

More info and screens

3

2. Health

2.1 Basic Checks

  • PSTX does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for PSTX has been increased compared to 1 year ago.
  • Compared to 1 year ago, PSTX has a worse debt to assets ratio.
PSTX Yearly Shares OutstandingPSTX Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M
PSTX Yearly Total Debt VS Total AssetsPSTX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M

2.2 Solvency

  • PSTX has an Altman-Z score of 0.21. This is a bad value and indicates that PSTX is not financially healthy and even has some risk of bankruptcy.
  • The Altman-Z score of PSTX (0.21) is better than 65.26% of its industry peers.
  • PSTX has a Debt/Equity ratio of 0.68. This is a neutral value indicating PSTX is somewhat dependend on debt financing.
  • Looking at the Debt to Equity ratio, with a value of 0.68, PSTX is doing worse than 77.42% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.68
Debt/FCF N/A
Altman-Z 0.21
ROIC/WACCN/A
WACC10.98%
PSTX Yearly LT Debt VS Equity VS FCFPSTX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 0 100M -100M 200M

2.3 Liquidity

  • PSTX has a Current Ratio of 3.20. This indicates that PSTX is financially healthy and has no problem in meeting its short term obligations.
  • PSTX has a Current ratio of 3.20. This is in the lower half of the industry: PSTX underperforms 62.43% of its industry peers.
  • PSTX has a Quick Ratio of 3.20. This indicates that PSTX is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 3.20, PSTX is doing worse than 60.49% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 3.2
Quick Ratio 3.2
PSTX Yearly Current Assets VS Current LiabilitesPSTX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M

More info and screens

4

3. Growth

3.1 Past

  • PSTX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 58.28%, which is quite impressive.
  • Looking at the last year, PSTX shows a very strong growth in Revenue. The Revenue has grown by 202.93%.
EPS 1Y (TTM)58.28%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%160%
Revenue 1Y (TTM)202.93%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%667.19%

3.2 Future

  • Based on estimates for the next years, PSTX will show a quite strong growth in Earnings Per Share. The EPS will grow by 16.75% on average per year.
  • PSTX is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 52.27% yearly.
EPS Next Y30.29%
EPS Next 2Y-11.11%
EPS Next 3Y-0.5%
EPS Next 5Y16.75%
Revenue Next Year217.39%
Revenue Next 2Y-3.31%
Revenue Next 3Y-22%
Revenue Next 5Y52.27%

3.3 Evolution

PSTX Yearly Revenue VS EstimatesPSTX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 500M 1B 1.5B
PSTX Yearly EPS VS EstimatesPSTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for PSTX. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for PSTX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PSTX Price Earnings VS Forward Price EarningsPSTX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PSTX Per share dataPSTX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-11.11%
EPS Next 3Y-0.5%

More info and screens

0

5. Dividend

5.1 Amount

  • PSTX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

POSEIDA THERAPEUTICS INC

NASDAQ:PSTX (1/7/2025, 8:07:14 PM)

After market: 9.54 +0.04 (+0.42%)

9.5

-0.06 (-0.63%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-07
Earnings (Next)N/A
Inst Owners55.52%
Inst Owner Change0%
Ins Owners0.89%
Ins Owner Change0%
Market Cap925.97M
Revenue(TTM)150.86M
Net Income(TTM)-60.76M
Analysts50
Price Target9.18 (-3.37%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)86.77%
Min EPS beat(2)23.01%
Max EPS beat(2)150.52%
EPS beat(4)4
Avg EPS beat(4)61.65%
Min EPS beat(4)23.01%
Max EPS beat(4)150.52%
EPS beat(8)6
Avg EPS beat(8)25.24%
EPS beat(12)9
Avg EPS beat(12)43.35%
EPS beat(16)12
Avg EPS beat(16)33.55%
Revenue beat(2)2
Avg Revenue beat(2)198.71%
Min Revenue beat(2)64.99%
Max Revenue beat(2)332.43%
Revenue beat(4)4
Avg Revenue beat(4)200.6%
Min Revenue beat(4)64.99%
Max Revenue beat(4)332.43%
Revenue beat(8)6
Avg Revenue beat(8)122.25%
Revenue beat(12)10
Avg Revenue beat(12)1069.67%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-5.26%
PT rev (3m)-35.71%
EPS NQ rev (1m)0%
EPS NQ rev (3m)8.28%
EPS NY rev (1m)0%
EPS NY rev (3m)32.74%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)10.15%
Revenue NY rev (1m)0%
Revenue NY rev (3m)69.87%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 6.14
P/FCF N/A
P/OCF N/A
P/B 10.62
P/tB 11.34
EV/EBITDA N/A
EPS(TTM)-0.63
EYN/A
EPS(NY)-1.72
Fwd EYN/A
FCF(TTM)-0.18
FCFYN/A
OCF(TTM)-0.15
OCFYN/A
SpS1.55
BVpS0.89
TBVpS0.84
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -20.7%
ROE -69.67%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-36.56%
ROA(5y)-40.69%
ROE(3y)-77.72%
ROE(5y)-80.34%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.51
Health
Industry RankSector Rank
Debt/Equity 0.68
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 38.31%
Cap/Sales 1.39%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.2
Quick Ratio 3.2
Altman-Z 0.21
F-Score4
WACC10.98%
ROIC/WACCN/A
Cap/Depr(3y)62.75%
Cap/Depr(5y)254.95%
Cap/Sales(3y)5.39%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)58.28%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%160%
EPS Next Y30.29%
EPS Next 2Y-11.11%
EPS Next 3Y-0.5%
EPS Next 5Y16.75%
Revenue 1Y (TTM)202.93%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%667.19%
Revenue Next Year217.39%
Revenue Next 2Y-3.31%
Revenue Next 3Y-22%
Revenue Next 5Y52.27%
EBIT growth 1Y54.31%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year15.16%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y30.3%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y27.41%
OCF growth 3YN/A
OCF growth 5YN/A

POSEIDA THERAPEUTICS INC / PSTX FAQ

What is the ChartMill fundamental rating of POSEIDA THERAPEUTICS INC (PSTX) stock?

ChartMill assigns a fundamental rating of 2 / 10 to PSTX.


Can you provide the valuation status for POSEIDA THERAPEUTICS INC?

ChartMill assigns a valuation rating of 0 / 10 to POSEIDA THERAPEUTICS INC (PSTX). This can be considered as Overvalued.


How profitable is POSEIDA THERAPEUTICS INC (PSTX) stock?

POSEIDA THERAPEUTICS INC (PSTX) has a profitability rating of 1 / 10.


What is the financial health of POSEIDA THERAPEUTICS INC (PSTX) stock?

The financial health rating of POSEIDA THERAPEUTICS INC (PSTX) is 3 / 10.